These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32848380)

  • 41. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Muro S; Suzuki M; Nakamura S; Wang JR; Garry EM; Sakamoto W; de Souza S
    Respir Res; 2021 Jun; 22(1):180. PubMed ID: 34140019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
    Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M
    BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
    Kawachi S; Fujimoto K
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
    [No Abstract]   [Full Text] [Related]  

  • 48. TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow.
    Mahler DA; Ludwig-Sengpiel A; Ferguson GT; de la Hoz A; Ritz J; Shaikh A; Watz H
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2455-2465. PubMed ID: 34511891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Kato M; Takizawa A; Sakamoto W; Grönke L; Tetzlaff K; Fukuchi Y
    Respir Investig; 2017 Mar; 55(2):121-129. PubMed ID: 28274527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study.
    Valipour A; Avdeev S; Barczyk A; Bayer V; Fridlender Z; Georgieva M; Kudela O; Medvedchikov A; Miron R; Sanzharovskaya M; Šileikienė V; Šorli J; Spielmanns M; Szalai Z
    Int J Chron Obstruct Pulmon Dis; 2021; 16():615-628. PubMed ID: 33731991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Tiotropium/Olodaterol in the Real World: A Post Hoc Subgroup Analysis After the First Year of Use.
    Sato A; Miyazaki A; Nakamura S
    Adv Ther; 2022 Oct; 39(10):4692-4706. PubMed ID: 35948844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
    Muruganandan S; Jayaram L
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
    COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
    Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
    BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K; Uchida M; Kato G; Takamori A; Kinoshita T; Yoshida M; Tajiri R; Kojima K; Inoue H; Kobayashi H; Sadamatsu H; Tashiro H; Tanaka M; Hayashi S; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2115-2126. PubMed ID: 32982204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
    McGarvey L; Niewoehner D; Magder S; Sachs P; Tetzlaff K; Hamilton A; Korducki L; Bothner U; Vogelmeier C; Koch A; Ferguson GT
    COPD; 2015; 12(5):484-93. PubMed ID: 25692310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
    Cheyne L; Irvin-Sellers MJ; White J
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009552. PubMed ID: 24043433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
    Melani AS
    Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT
    Buhl R; Dreher M; Korn S; Taube C; Stock C; Zehendner CM; Kondla A; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2601-2608. PubMed ID: 33122898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.